Oseltamivir
- PDF / 170,168 Bytes
- 1 Pages / 595.245 x 841.846 pts (A4) Page_size
- 60 Downloads / 161 Views
1 S
Immune thrombocytopenic purpura following off-label use: case report A 32‐year‐old woman developed immune thrombocytopenic purpura (ITP) while receiving off-label treatment with oseltamivir for COVID-19 infection. On 3 February 2020, the woman developed cough, fever and fatigue. The fever resolved after she received an unspecified medication. On 5 February 2020, she presented to a hospital in China for evaluation. Examinations were indicative of pneumonia and low platelet count. During home isolation, she received off-label therapy with oseltamivir [route and dosage not stated] with concomitant traditional Chinese medicine. On 7 February 2020, a diagnosis of COVID-19 infection was confirmed. On 16 February 2020, she presented with small bleeding spots on the skin in the entire body, predominantly on the lower limbs, requiring hospitalisation. On 19 February 2020, she was shifted to another hospital, and was diagnosed with ITP [duration of treatment to reaction onset not stated]. The woman received treatment with methylprednisolone and was administered platelets, and the rash resolved gradually. On 3 March 2020 (after a 16 day history of rash), she was again hospitalised due to moderate COVID‐19 and ITP (lowest platelet count of 64×109/L). Improvement was noted in her condition with the methylprednisolone therapy; hence, the methylprednisolone therapy was continued. On 10 March 2020, blood tests showed a platelet count of 119×109/L and absolute neutrophil count of 6.41×109/L. Afterwards, she met the discharge standards of COVID-19. Blood routine examination on 12 March 2020, showed stable platelet count at 113×109/L. She was then discharged on 14 March. Yang Y, et al. A rare case of immune thrombocytopenic purpura, secondary to COVID-19. Journal of Medical Virology 92: 2358-2360, No. 11, Nov 2020. Available from: URL: http://doi.org/10.1002/jmv.26051 803514387
0114-9954/20/1830-0001/$14.95 Adis © 2020 Springer Nature Switzerland AG. All rights reserved
Reactions 14 Nov 2020 No. 1830
Data Loading...
